Dr. Al-Batran on Future of Treatment in Gastric Cancer

Salah-Eddin Al-Batran, MD
Published: Friday, Mar 10, 2017



Salah-Eddin Al-Batran, MD, medical oncologist and director at the Institute of Clinical Cancer Research—Frankfurt, Germany, discusses the future of treatment in gastric cancer.

Immunotherapies continue to show promise in this landscape, with the results of the ONO-4538-12 trial demonstrating the activity of nivolumab (Opdivo) in patients with unresectable advanced or recurrent gastric cancer.

Al-Batran says that the emergence of these new agents in immunotherapy will hopefully improve survival in this disease.
 


Salah-Eddin Al-Batran, MD, medical oncologist and director at the Institute of Clinical Cancer Research—Frankfurt, Germany, discusses the future of treatment in gastric cancer.

Immunotherapies continue to show promise in this landscape, with the results of the ONO-4538-12 trial demonstrating the activity of nivolumab (Opdivo) in patients with unresectable advanced or recurrent gastric cancer.

Al-Batran says that the emergence of these new agents in immunotherapy will hopefully improve survival in this disease.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: The Next Generation in Renal Cell Carcinoma Treatment: An Oncology Nursing Essentials WorkshopJul 31, 20181.5
Publication Bottom Border
Border Publication
x